Exhibit 99.1 Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity —Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension — May 14, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today reported financial results for the quarter ended March 31, 2 ...